Table 5.
Summary of clinical assays of broad-spectrum antiviral against Enteroviruses.
| Publication Date | Type of Study * | Virus/Disease | Type of Infection (Time to Treatment Interval) † | Drug | Pharmaceutical Form | Patient Age | Ref. |
|---|---|---|---|---|---|---|---|
| March 1973 | DB PC phase II | RV-A9, RV-A13 | Inoculation (−1 day) | Isoprinosine | Oral tablet | 18–50 years old | [87] |
| April 1974 | DB PC phase II | RV-A32, RV-B44 | Inoculation | Isoprinosine | Oral tablet | 25–48 years old | [88] |
| March 1977 | Rdm DB PC phase II | RV-A21 | Inoculation | Isoprinosine | Oral tablet | >18 years old | [89] |
| 18 July 2018 | Rdm DB PC phase III | EV, RV | Naturally occurred (+40 h) | Nitazoxanide | Oral tablets | >12 years old | [90] |
| 13 May 2020 | Rdm DB PC phase III | EV, RV | Naturally occurred (+72 h) | Nitazoxanide | Oral tablets | >12 years old | [91] |
| May 1970 | Rdm DB PC phase II | RV-A9 | Inoculation (−1 day) | UK2054 | Oral formulation | NS | [92] |
| December 1973 | DB PC phase II | RV-A24 | Inoculation (−1 day) | DIQA | Oral capsule | 21–42 years old | [93] |
| 14 January 2017 | Rdm DB PC phase II | Upper respiratory | Naturally occurred | ARM-1 | Oral spray | 18–43 years old | [94] |
* Rdm = randomized; DB = double–blind; PC = placebo-controlled. † Negative delay means that the treatment began before the virus challenge or symptoms onset. The positive delay means that the treatment began after the virus challenge or symptoms onset. NS = not specified.